Caffeic acid — Caffeic acid is a dietary hydroxycinnamic acid polyphenol present in coffee, fruits, vegetables, and many herbs, and is also generated from hydrolysis of chlorogenic acids. It is formally classified as a small-molecule plant phenolic acid with redox-active, anti-inflammatory, and signal-modulating properties. Standard abbreviations include CA for caffeic acid; it should be distinguished from CAPE (caffeic acid phenethyl ester), which is a different propolis-derived ester with overlapping but not identical pharmacology. In cancer research, CA is best viewed as a pleiotropic preclinical modulator of inflammatory signaling, stress adaptation, metabolism, apoptosis, invasion, and angiogenesis, with translation limited by rapid conjugation and generally low free-aglycone systemic exposure.
Primary mechanisms (ranked):
Bioavailability / PK relevance: CA is absorbable in humans, but after oral intake much of the circulating material appears rapidly as sulfate, glucuronide, and methylated metabolites rather than persistent free aglycone. Peak plasma timing is typically early, and delivery is constrained less by gut uptake than by fast metabolic conversion and short-lived free exposure.
In-vitro vs systemic exposure relevance: Many anticancer studies use tens of micromolar CA, and some mechanistic claims depend on 50–100 µM or higher conditions that are not reliably reproduced as sustained free systemic exposure after ordinary oral intake. Accordingly, anti-inflammatory/adjuvant interpretations translate better than claims requiring strong direct tumor-cidal free-drug concentrations; metal-assisted pro-oxidant effects are especially context-dependent.
Clinical evidence status: Primarily preclinical. The cancer evidence base consists mainly of cell and animal studies, with some adjunct/chemosensitization signals. Human oncology evidence remains very limited; at least one registered esophageal squamous cell carcinoma trial has been reported, but caffeic acid is not an established anticancer drug or standard adjunct.
| Rank | Pathway / Axis | Cancer Cells | Normal Cells | TSF | Primary Effect | Notes / Interpretation |
|---|---|---|---|---|---|---|
| 1 | IL-6 / JAK / STAT3 signaling | ↓ | ↔ / ↓ inflammatory tone | R, G | Anti-survival transcription | One of the cleaner current cancer axes for CA itself; suppression links to reduced proliferation, migration, and anti-apoptotic signaling. |
| 2 | NF-κB inflammatory transcription | ↓ | ↓ inflammatory stress | R, G | Anti-inflammatory / anti-survival | Consistent across reviews and multiple models, but CA is generally a weaker and less canonical NF-κB inhibitor than CAPE. |
| 3 | ROS redox modulation | ↔ / ↑ (context-dependent) | ↓ oxidative injury | P, R | Redox reprogramming | CA is usually antioxidant in normal tissues, yet can become pro-oxidant in tumor or copper-rich settings; direction is strongly model- and dose-dependent. |
| 4 | ERK and PI3K / AKT survival signaling | ↓ | ↔ | R, G | Growth and resistance suppression | Frequently appears upstream of reduced clonogenicity, apoptosis sensitization, and lower chemoresistance in acidic or stressed tumor states. |
| 5 | Mitochondrial apoptosis | Bax ↑, caspase-3 ↑, Bcl-2 ↓ | ↔ / relative sparing | G | Cell death execution | Usually a downstream endpoint rather than the first event; strongest in susceptible cell lines and higher in-vitro exposure. |
| 6 | Cell-cycle machinery | cyclin D ↓, arrest ↑ | ↔ | G | Cytostasis | Phase of arrest varies by model; best treated as a secondary phenotype following signaling and redox changes. |
| 7 | MMP / EMT / invasion programs | MMP2/9 ↓, EMT ↓, migration ↓ | ↔ | G | Anti-invasive effect | Supported in several tumor models, though part of the older invasion literature is stronger for caffeic-acid derivatives than for CA itself. |
| 8 | STAT3-HIF-1α-VEGF angiogenesis axis | HIF-1α ↓, VEGF ↓ | ↔ | G | Anti-angiogenic support | Includes in-vivo support in renal carcinoma xenograft work; useful mechanistically, but still preclinical. |
| 9 | AMPK and tumor energy metabolism | AMPK ↑, glycolytic dependence ↓ | ↔ / context-dependent | R, G | Metabolic stress | Relevant in selected cancers rather than universally. Better framed as model-dependent metabolic rewiring than as a universal glycolysis inhibitor. |
| 10 | NRF2 antioxidant response | ↔ / ↑ (context-dependent) | ↑ | R, G | Stress adaptation | Important for normal-cell protection and toxicity mitigation. In tumors, NRF2 activation may be beneficial, neutral, or counterproductive depending on context, so it is not a uniformly favorable anticancer axis. |
| 11 | Clinical Translation Constraint | Free CA exposure limited | Conjugated metabolites predominate | — | PK limitation | Human absorption occurs, but circulating chemistry is dominated by rapid conjugation. Many direct in-vitro tumoricidal concentrations likely exceed sustained free systemic levels achievable by routine oral dosing. |
Time-Scale Flag (TSF): P / R / G